XBiotech posts Phase 1 results for Natrunix dose-escalation study in healthy volunteers
Results were first posted for a completed Phase 1 trial testing subcutaneous Natrunix across three dose cohorts against placebo.
XBiotech had one clinical trial update this week.
- Natrunix (XB2001), a Phase 1 study in healthy volunteers, had results first posted on 2026-08-14 after the trial was marked completed. The study was an open-label, placebo-controlled dose escalation study evaluating safety and pharmacokinetics of Natrunix given via subcutaneous injection in healthy subjects1, enrolling 8 healthy subjects per cohort, including six for Natrunix and two for placebo, across three cohorts for a total of 24 healthy volunteers1. The primary outcome tracked the number of participants with treatment emergent adverse events from Day 0 up to Day 281.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.